Lantheus Holdings, Inc. (LNTH) Business Profile

What it does

Lantheus Holdings is a healthcare company focused on radiopharmaceuticals: products that use radioactive material to help clinicians see or treat disease. Its commercial portfolio is primarily diagnostic, helping clinicians examine patients for cancer, heart conditions and signs associated with Alzheimer’s disease. The company is headquartered in Massachusetts, and Mary Anne Heino is its chief executive officer while the board searches for a successor.

Its prostate cancer imaging agent PYLARIFY is used with PET scans to locate certain cancer lesions. Neuraceq is a PET imaging agent used to estimate the density of amyloid plaques in the brains of adults being evaluated for Alzheimer’s disease or other causes of cognitive decline. DEFINITY is different: it is an injectable ultrasound-enhancing agent used to improve heart images when an echocardiogram is otherwise difficult to interpret.

The company sells primarily to hospitals, independent imaging centers and government facilities. Its products are used by specialists including cardiologists, oncologists, radiologists and nuclear medicine physicians. Lantheus also supplies imaging tools for research, licenses product rights to partners and provides contract development and manufacturing services through its Evergreen subsidiary.

Lantheus sold its SPECT imaging business, including several older commercial products, on January 1, 2026. Its remaining commercial products include PET radiodiagnostics and ultrasound microbubbles.

How it makes money

Lantheus earns revenue by selling diagnostic products for use in individual imaging procedures. PYLARIFY is supplied through a network of PET manufacturing facilities, which prepare patient-specific doses. DEFINITY is an injectable agent used during echocardiograms, while Neuraceq is a radioactive agent used in brain PET scans. Revenue depends on continued use of these products and on the prices and reimbursement arrangements applicable to them.

The company also earns money from pharmaceutical companies and academic institutions that use its commercial or investigational imaging products as research tools. Its partnerships can generate license fees, royalties and milestone payments. Evergreen adds contract development and manufacturing revenue. For example, Lantheus licensed its prostate cancer imaging agent to GE Healthcare in Japan in exchange for an upfront fee, development milestones and tiered royalties based on product sales.

Q1 2026 revenue was $377.3 million. Oncology, consisting of PYLARIFY, contributed $240.9 million for the quarter. Lantheus has reorganized its revenue reporting into oncology, neurology, cardiology, and strategic partnerships and other, with a separate category for the divested SPECT business in prior-period results.

Payment policies matter to product sales. Medicare continues to provide separate payment for PYLARIFY in the hospital outpatient setting for eligible traditional fee-for-service patients. Neuraceq’s Medicare payment rate in that setting is below the rates for competing products. Product sales can recur as healthcare providers perform additional scans, while milestone payments depend on the terms and achievements in individual agreements.

Customers and how it sells

Lantheus sells primarily to hospitals, independent imaging centers and government facilities in the United States. Its products are used by clinicians across several specialties, including cardiology, neurology, oncology, radiology, urology and nuclear medicine. Pharmaceutical companies and academic institutions are also customers or collaborators when they use Lantheus imaging products in clinical trials.

No customer accounted for greater than 10% of revenues for the year ended December 31, 2025. For that year, approximately 5.4% of revenues came from outside the United States.

Outside the United States, Lantheus generally uses a combination of direct distribution, third-party distributors and licenses granting partners exclusive development and commercialization rights in specified markets. Its distribution relationships cover Europe, Canada, Australia, Asia-Pacific, Central America and South America. The company has offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, in addition to its Massachusetts headquarters.

Access to individual products depends on local approvals and supply arrangements. Neuraceq, for example, is commercially approved in markets including the United States, Canada, the European Union, the United Kingdom, China and Japan. Lantheus has licensed Neuraceq to partners in selected markets, including China, Japan and South Korea.

Suppliers and costs

PET imaging agents require manufacturing and distribution arrangements that account for their radioactive ingredients. PYLARIFY is made through a network of commercial and academic PET manufacturing facilities. Each facility producing it is separately approved by the FDA, and a radiopharmacist prepares patient-specific doses after manufacturing and quality testing. Neuraceq is also made through a network of approved facilities; its F-18 ingredient has a 110-minute half-life, making rapid production and distribution necessary.

Lantheus relies on Jubilant HollisterStier as a significant DEFINITY supplier and also manufactures DEFINITY at its North Billerica facility. Evergreen provides contract development and manufacturing services. For the PNT2003 candidate, partner POINT is responsible for manufacturing, subject to exceptions in its agreement with Lantheus.

For the year ended December 31, 2025, approximately 12.0% of the company’s cost of goods sold was sourced outside the United States. In Q1 2026, adjusted gross profit margin was 67.0%. Lantheus said the inclusion of Evergreen and Neuraceq affected the quarter’s margin, while operating expenses increased partly because of acquired operations and spending on its expanded clinical portfolio.

Competitive position

PYLARIFY competes with other prostate cancer imaging agents. Lantheus names Telix Pharmaceuticals, Blue Earth Diagnostics and Novartis among its principal competitors. Neuraceq competes with beta-amyloid PET imaging agents from Eli Lilly and GE Healthcare. DEFINITY competes with products from GE Healthcare and Bracco, as well as imaging without an ultrasound-enhancing agent and other imaging methods.

Lantheus estimated that DEFINITY had over 80% share of the U.S. segment for ultrasound-enhancing agents in echocardiography procedures as of December 31, 2025. The company also faces potential generic competition. PYLARIFY’s new chemical entity exclusivity expires in May 2026, although its U.S. listed composition-of-matter patents extend beyond that date.

Our reading: DEFINITY’s share and established activation-device workflow support a meaningful competitive position, although competing agents and other imaging methods remain available. Our reading: PYLARIFY’s approved manufacturing network and listed patents provide protection, but competing tracers and potential generic entry limit its durability. Our reading: Neuraceq can use Lantheus’s existing customer relationships, but its reimbursement disadvantage and established rivals constrain that benefit.

The company also names Novartis, ITM Radiopharma, Curium and RayzeBio as potential competitors for PNT2003 if it is commercialized.

Growth opportunities

Lantheus is pursuing growth through its existing diagnostic products, an expanded manufacturing footprint and new imaging candidates. For Neuraceq, the company plans to reach existing PYLARIFY customers, add manufacturing capacity and increase the number of sites. It also ties Neuraceq’s growth to wider use of amyloid PET imaging and anti-amyloid therapies.

The FDA approved a new PYLARIFY formulation, PYLARIFY TrueView, in March 2026. Lantheus plans a geographic, site-by-site transition beginning in the fourth quarter of 2026, with one of the two products available in each market at a time. The company says the new formulation can allow larger batches at facilities with high-energy cyclotrons. Before customers begin ordering it, Lantheus wants insurance coverage, operational coding and coverage systems, and transitional pass-through payment in place.

In its pipeline, MK-6240 is a tau-targeted PET imaging candidate for patients with cognitive impairment being evaluated for Alzheimer’s disease. The FDA has set an August 13, 2026 target action date for its application. Lantheus is also developing the LNTH-2401 and LNTH-2402 diagnostic and therapeutic pair for prostate cancer.

PNT2003, a candidate for neuroendocrine tumors, received tentative FDA approval in March 2026. Lantheus says launch timing depends on final approval, the Hatch-Waxman stay, related legal proceedings and commercial readiness. The company says its strategy is centered on radiodiagnostics while it evaluates alternatives for its radiotherapeutic assets.

Structural risks

• PYLARIFY competition and supply: Continued revenue depends on facilities meeting demand at the times customers need doses, adequate payment, differentiation from competitors and whether a generic enters the market.
• Reimbursement: Customers depend on third-party payors, particularly Medicare. Reduced coverage or payment rates could affect demand; Neuraceq’s hospital outpatient Medicare payment rate is below those of competing products.
• Manufacturing and regulation: Production interruptions, facility shutdowns or difficulties obtaining approvals could limit supply or delay products. Radioactive imaging agents also require rapid manufacturing and distribution.
• Intellectual property and litigation: Patents may be challenged, may not provide competitive protection or may be costly to defend. PNT2003’s final approval and launch remain subject to the stay and related legal proceedings.
• Acquisitions and integration: Acquired businesses and products may underperform expectations, while combining operations, personnel and systems can take management time and create unforeseen liabilities.
• Development and commercialization: New products require regulatory approvals and customer readiness. Lantheus’s planned transition to PYLARIFY TrueView also depends on securing coverage, coding and payment before customers order it.

Bottom line

Our reading

Lantheus is a diagnostic products business built around recurring imaging use, with PYLARIFY central to its current revenue and DEFINITY providing a separate cardiology franchise. [item1] [call_prepared] Its opportunities in Alzheimer’s imaging and new formulations depend on manufacturing reach, reimbursement and regulatory execution, while competition and potential generic entry put pressure on established products. [item1] [item1a] [call_qa]